» Articles » PMID: 31857361

Autoantibody-mediated Desialylation Impairs Human Thrombopoiesis and Platelet Lifespan

Overview
Journal Haematologica
Specialty Hematology
Date 2019 Dec 21
PMID 31857361
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Immune thrombocytopenia is a common bleeding disease caused by autoantibody-mediated accelerated platelet clearance and impaired thrombopoiesis. Accumulating evidence suggests that desialylation affects platelet life span in immune thrombocytopenia. Herein, we report on novel effector functions of autoantibodies from immune thrombocytopenic patients which might interfere with the clinical picture of the disease. Data from our study show that a subgroup of autoantibodies is able to induce cleave of sialic acid residues from the surface of human platelets and megakaryocytes. Moreover, autoantibody-mediated desialylation interferes with the interaction between cells and extracellular matrix proteins leading to impaired platelet adhesion and megakaryocyte differentiation. Using a combination of ex vivo model of thrombopoiesis, a humanized animal model, and a clinical cohort study, we demonstrate that cleavage of sialic acid induces significant impairment in production, survival as well as function of human platelets. These data may indicate that prevention of desialylation should be investigated in the future in clinical studies as a potential therapeutic approach to treat bleeding in immune thrombocytopenia.

Citing Articles

Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.


Health-related quality of life and complications of corticosteroid treatment in patients with immune thrombocytopenia in two teaching hospitals in Ethiopia: a cross-sectional study.

Beyene D, Sisay E, Fentie A, Gebremedhin A Front Med (Lausanne). 2024; 11:1423161.

PMID: 39564500 PMC: 11573527. DOI: 10.3389/fmed.2024.1423161.


Treatment outcomes and adherence to treatment in patients with immune thrombocytopenia in two Ethiopian teaching hospitals: a retrospective cohort study.

Beyene D, Sisay E, Fentie A, Gebremedhin A Sci Rep. 2024; 14(1):11917.

PMID: 38789461 PMC: 11126412. DOI: 10.1038/s41598-024-62372-w.


Immune attack on megakaryocytes in immune thrombocytopenia.

Petito E, Gresele P Res Pract Thromb Haemost. 2024; 8(1):102345.

PMID: 38525349 PMC: 10960061. DOI: 10.1016/j.rpth.2024.102345.


Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report.

Liu L, Zhang B, Song C, Li P, Yang M, Ren X Ann Hematol. 2023; 103(2):405-408.

PMID: 38095655 DOI: 10.1007/s00277-023-05581-z.